Published Aug 08, 2018

Harbour BioMed inks $350 million deal for rights to A167

Member News
Copy The Link to the  Article
Harbour BioMed inks $350 million deal for rights to A167
Copy The Link to the  Article

Related or similar articles

View more News
August 8, 2018

Harbour BioMed inks $350 million deal for rights to A167

USA-based Harbour BioMed has entered into an exclusive strategic partnership with China’s Sichuan Kelun-Biotech Biopharmaceutical to develop and commercialize A167
Member News
June 18, 2024

Labshares Announces Key Leadership Additions: Devon Lagasse Joins as VP of Growth and Emma Orfanos Is Promoted to Manager of Business Development

Press Releases
June 12, 2019

Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development

The MoU was signed during the official, 40thanniversary celebration ceremony of the Shanghai-Rotterdam Sister City Relationship.
Member News